What Happened?
Camarillo, CA-based ImmPACT Bio USA Appointed Sylvain Roy as Chief Technology Officer
About the Company
ImmPACT-Bio is pioneering a novel strategy to surmount a major challenge compromising current Chimeric Antigen Receptor T-cell (CAR-T) therapy. Our technology addresses the need to differentiate cancerous from non-cancerous tissues impacting the safety of the treatment which is to date a major limitation in reaching effectiveness.
About the Person
Sylvain Roy is Chief Technology Officer at ImmPACT Bio USA. Previously, Sylvain held various senior IT leadership roles in the industry.
Info Source
News
Short Profile